Clinical Trial Update: Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating aprotinin to reduce transfusion requirements in patients undergoing lung or esophageal cancer surgery has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Lung Cancer

Drugs mentioned

• Aprotinin (Trasylol) (aprotinin)

Snippet

Sponsor: Bayer | Conditions: Blood Loss, Surgical | Phase 3 | Status: TERMINATED